Neuragen® gel versus placebo in the relief of neuropathic foot pain

ISRCTN ISRCTN37736407
DOI https://doi.org/10.1186/ISRCTN37736407
Secondary identifying numbers 32438
Submission date
01/11/2009
Registration date
09/11/2009
Last edited
09/11/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Li Li
Scientific

Department of Kinesiology
Louisiana State University
112 Long Field House
Baton Rouge
70803
United States of America

Email lli3@lsu.edu

Study information

Study designDouble-blind randomised placebo-controlled clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details provided to request a patient information sheet
Scientific titleThe effectiveness of Neuragen® gel versus placebo in the relief of neuropathic foot pain: a double-blind randomised placebo-controlled clinical trial
Study objectivesNeuragen® gel is more effective in relieving neuropathic foot pain than placebo.
Ethics approval(s)Institutional Review Board of Louisiana State University approved on the 15th September 2009 (ref: 2754)
Health condition(s) or problem(s) studiedPeripheral neuropathy
InterventionThis is a double blind randomised clinical trial. The company pre-packages the treatments in two identical containers labeled A and B; each contains one application of the topical Neuragen® gel and placebo. A or B will be applied to the foot sole of the participants only once each, at least seven days apart between the two applications. Foot pain will be recorded 30 minutes before, 30 minutes after and every hour on the hour for up to 8 hours.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II/III
Drug / device / biological / vaccine name(s)Neuragen® gel
Primary outcome measureLevel of pain on a 0 - 10 visual pain scale, measured 30 minutes before and after the application of of the treatment, and every hour thereafter for 8 hours.
Secondary outcome measuresDuration of pain reduction, measured on a 0 - 10 visual pain scale which will be used every hour on the hour for up to 8 hours.
Overall study start date09/11/2009
Completion date31/10/2010

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants60
Key inclusion criteria1. Male and female aged over 21 years
2. Diagnosed with neuropathic pain more 3 months
3. Pain level between 5 - 9 on a 0 - 10 visual pain scale
4. Does not have mental and communication impairments
Key exclusion criteria1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairments
Date of first enrolment09/11/2009
Date of final enrolment31/10/2010

Locations

Countries of recruitment

  • United States of America

Study participating centre

Department of Kinesiology
Baton Rouge
70803
United States of America

Sponsor information

Origin BioMed, Inc. (Canada)
Industry

5126 Duke Street
Suite 300
Halifax
B3J 1N7
Canada

Email mclellan@originbiomed.com
Website http://www.originbiomed.com/canada-en/
ROR logo "ROR" https://ror.org/008mcnd42

Funders

Funder type

Industry

Origin BioMed, Inc. (Canada)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan